Bart Biesmans
Impact in
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- HER2/EGFR in Cancer Research
-
- Genetic factors in colorectal cancer
Papers in
- Oncology 15
- Colorectal Cancer Treatments and Studies 15
-
- Cancer Genomics and Diagnostics 4
- Protease and Inhibitor Mechanisms 1
- Co-authors
- Sabine Tejpar (11 shared papers)Eric Van Cutsem (8 shared papers)Wendy De Roock (9 shared papers)Marc Peeters (4 shared papers)Hubert H. Piessevaux (4 shared papers)Yves Humblet (4 shared papers)Gert De Hertogh (3 shared papers)Nicola Personeni (2 shared papers)
- Journals
- Clinical Cancer Research (2 papers)Journal of Clinical Oncology (2 papers)Annals of Oncology (2 papers)Journal of Molecular Diagnostics (2 papers)Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin (1 paper)
- Partner nations
- BelgiumSwitzerlandGreece
In The Last Decade
Bart Biesmans
17 papers receiving 4.4k citations
Bart Biesmans's Hit Papers
Peers
Comparison fields: 5 of 75
- Oncology 3.5k
- Pathology and Forensic Medicine 606
- Cancer Research 458
- Pulmonary and Respiratory Medicine 237
- Molecular Biology 399
Countries citing papers authored by Bart Biesmans
This map shows the geographic impact of Bart Biesmans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Biesmans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Biesmans more than expected).
Fields of papers citing papers by Bart Biesmans
This network shows the impact of papers produced by Bart Biesmans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Biesmans. The network helps show where Bart Biesmans may publish in the future.
Co-authors
The 25 scholars most cited alongside Bart Biesmans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Hit paper breakdown → | 2010 | 1821 |
| 2 | Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial Hit paper breakdown → | 2009 | 992 |
| 3 | KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Hit paper breakdown → | 2007 | 722 |
| 4 | 2009 | 305 | |
| 5 | 2009 | 253 | |
| 6 | 2008 | 140 | |
| 7 | Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial | 2010 | 73 |
| 8 | 2009 | 72 | |
| 9 | 2009 | 38 | |
| 10 | 2012 | 26 | |
| 11 | 2013 | 21 | |
| 12 | 2012 | 13 | |
| 13 | Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease. | 2008 | 11 |
| 14 | 2012 | 10 | |
| 15 | 2015 | 3 | |
| 16 | PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer | 2009 | 1 |
| 17 | 2012 | 1 |
About Bart Biesmans
Bart Biesmans is a scholar working on Oncology, Cancer Research, Physiology, Molecular Biology and Nuclear Energy and Engineering, having authored 17 papers that have together received 4.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (15 papers), Cancer Genomics and Diagnostics (4 papers), Clinical Laboratory Practices and Quality Control (3 papers), Protease and Inhibitor Mechanisms (1 paper) and Protein Tyrosine Phosphatases (1 paper). The work is most often cited by research in Oncology (3.5k citations), Pathology and Forensic Medicine (606 citations), Cancer Research (458 citations), Pulmonary and Respiratory Medicine (237 citations) and Molecular Biology (399 citations). Bart Biesmans has collaborated with scholars based in Belgium, Switzerland and Greece. Frequent co-authors include Sabine Tejpar, Eric Van Cutsem, Wendy De Roock, Marc Peeters, Hubert H. Piessevaux, Yves Humblet, Gert De Hertogh, Nicola Personeni, Jef De Schutter and David Cunningham. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Journal of Molecular Diagnostics and Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.